Abstract
BACKGROUND:
The aim of the study was to evaluate survival and perioperative outcomes of metastatic prostate cancer (mPCa) patients treated with surgery or androgen deprivation treatment (ADT) only.
METHODS:
We retrospectively selected 47 metastatic PCa patients treated at a single center (Mayo Clinic, Rochester, MN) by two urologists (RJK and EK) between 2007 and 2014. Overall, 31 (66%) underwent radical prostatectomy (RP) with or without adjuvant therapies and 16 (34%) underwent ADT only. Surgical patients were treated by a single surgeon (RJK). Complications and functional outcomes were recorded for surgery group. Cancer-specific mortality (CSM) was analyzed by Kaplan–Meier estimation. Univariable Cox regression analyses were used to test the risk factors associated with CSM in mPCa patients treated with RP.
RESULTS:
Median age at diagnosis was 61 years. During median follow-up 38.8 months, 12 deaths were recorded. At 5 years, the overall CSM-free survival rate of the whole cohort was 57.9%. When patients were stratified according to the treatment, CSM-free survival rate at 5 years was 62% and 46% for patients who underwent surgery and ADT, respectively (P=0.3). Median length of stay was 3 days, with a 30 days readmission rate of 9.7%. The 30-day all complication rate was 29% (n=9). Specifically, we recorded: 2 lymphoceles (6.5%), 2 wound infection (6.5%), 2 ileus (6.5%), 2 hematoma (6.5%) and 1 anastomosis leak (3.2%). Within 90 days after surgery, 2 (6.5%) and 5 (16.1%) patients needed 1–2 supportive and 3 or more pads, respectively. However, continence was achieved by all treated patients during the follow-up period.
CONCLUSIONS:
We demonstrated the feasibility of local surgical treatment of primary tumor in mPCa patients. However, in the short term, no survival benefits have been observed for patients treated with surgery when compared with patients treated with ADT only. Further prospective studies are warranted to explore the treatment of M1a/M1b prostate cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014; 12: 686–718.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467–479.
De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A . Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007; 9: 113–123.
Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818–823.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–1659.
Aben KKH, Heskamp S, Janssen-Heijnen ML, Koldewijn EL, Van Herpen CM, Kiemeney LA et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011; 47: 2023–2032.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–1259.
Temple LKF, Hsieh L, Wong WD, Saltz L, Schrag D . Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22: 3475–3484.
Shao Y-HJ, Kim S, Moore DF, Shih W, Lin Y, Stein M et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol 2014; 65: 693–700.
Fossati N, Trinh Q-D, Sammon J, Sood A, Larcher A, Sun M et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015; 67: 3–6.
Gratzke C, Engel J, Stief CG . Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014; 66: 602–603.
Culp SH, Schellhammer PF, Williams MB . Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65: 1058–1066.
Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a seer-medicare analysis. J Urol 2015; 194: 378–385.
Antwi S, Everson TM . Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 2014; 38: 435–441.
Heidenreich A, Pfister D, Porres D . Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015; 193: 832–838.
Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P et al. A Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2015; 69: 788–794.
Dindo D, Demartines N, Clavien P-A . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.
Psaila B, Lyden D . The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285–293.
Langley RR, Fidler IJ . The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527–2535.
Fidler IJ . The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458.
Gandaglia G, Fossati N, Dell’Oglio P, Moschini M, Cucchiara V, Suardi N et al. Rationale for local treatment in the management of metastatic prostate cancer. Curr Opin Support Palliat Care 2016; 10: 266–272.
Moschini M, Soria F, Briganti A, Shariat SF . The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer Prostatic Dis 2016; doi:10.1038/pcan.2016.52.
Löppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 2016; doi:10.1016/j.eururo.2016.04.031.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Moschini, M., Morlacco, A., Kwon, E. et al. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis 20, 117–121 (2017). https://doi.org/10.1038/pcan.2016.63
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2016.63
This article is cited by
-
Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer
Current Urology Reports (2023)
-
Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis
World Journal of Surgical Oncology (2022)
-
The impact of low pressure pneumoperitoneum in robotic assisted radical prostatectomy: a prospective, randomized, double blinded trial
World Journal of Urology (2021)
-
Reduction in postoperative ileus rates utilizing lower pressure pneumoperitoneum in robotic-assisted radical prostatectomy
Journal of Robotic Surgery (2019)